ArticleFrontiers in immunology2026

A low-dose immunotherapy targeting Fc gamma Receptors and heparan sulfate proteoglycan to impact myeloid cells and control cancers with diverse immunosuppressive profiles.

Nora Kakwata-Nkor Deluce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.